Vivani Medical (NASDAQ:VANI) Issues Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Vivani Medical (NASDAQ:VANI) posted its quarterly earnings data on Thursday. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01, FiscalAI reports.

Vivani Medical Stock Performance

Shares of NASDAQ:VANI traded down $0.05 during trading on Thursday, reaching $1.08. The stock had a trading volume of 270,967 shares, compared to its average volume of 314,616. Vivani Medical has a 1-year low of $0.91 and a 1-year high of $1.92. The stock has a market cap of $84.42 million, a PE ratio of -2.40 and a beta of 3.17. The business has a fifty day moving average price of $1.26 and a 200-day moving average price of $1.36.

Insider Buying and Selling

In other news, Director Gregg Williams acquired 1,737,765 shares of the firm’s stock in a transaction on Thursday, January 15th. The shares were bought at an average price of $1.14 per share, for a total transaction of $1,981,052.10. Following the acquisition, the director owned 26,564,109 shares of the company’s stock, valued at approximately $30,283,084.26. This trade represents a 7.00% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Over the last three months, insiders acquired 4,664,347 shares of company stock valued at $5,666,549. 46.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of VANI. State Street Corp grew its holdings in shares of Vivani Medical by 12.5% in the fourth quarter. State Street Corp now owns 144,865 shares of the company’s stock valued at $178,000 after purchasing an additional 16,070 shares during the period. Susquehanna International Group LLP raised its stake in Vivani Medical by 100.5% during the third quarter. Susquehanna International Group LLP now owns 32,314 shares of the company’s stock worth $46,000 after purchasing an additional 16,200 shares during the period. Citadel Advisors LLC acquired a new position in Vivani Medical in the 3rd quarter valued at about $26,000. Jane Street Group LLC acquired a new position in Vivani Medical in the 4th quarter valued at about $60,000. Finally, Renaissance Technologies LLC grew its stake in shares of Vivani Medical by 118.4% in the 4th quarter. Renaissance Technologies LLC now owns 97,985 shares of the company’s stock valued at $121,000 after buying an additional 53,127 shares during the period. Hedge funds and other institutional investors own 6.78% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vivani Medical in a research report on Friday, January 9th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Vivani Medical has a consensus rating of “Hold” and a consensus price target of $4.00.

Vivani Medical Company Profile

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.